DMAC vs TFC · $157.4M cap vs rev $24.54B
DiaMedica Therapeutics Inc (DMAC) versus TFC (TFC) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
TFC (TFC) common stock.
DMAC does not have a complete income-statement cache yet.
Latest reported TFC revenue for 2025-12-31 was $24.54B. Net income was $5.31B. Revenue was down 2.1% from 2024-12-31 to 2025-12-31. TFC currently screens at market cap $0.
DMAC currently screens at market cap $157.4M. TFC currently screens at market cap $0.
Not investment advice. Open the DMAC and TFC stock pages for the full models.
Not investment advice.